Skip to main content

Table 7 Univariable and multivariable survival analysis for PFS using Cox proportional hazards models

From: Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC

Group Immune Biomarker Univariable Multivariable
HR (95% CI) p-value HR (95% CI) p-value
Cohort A ALCs
> = 800
< 800
5.08 (1.62, 15.92) 0.005 4.25 (1.21, 14.87) 0.024
CD4 plus CD8 counts
> = 500
< 500
6.36 (1.76, 22.97) 0.005 8.89 (1.89, 41.86) 0.006
PD-L1 IHC
> = 50%
< 50%
1.17 (0.42, 3.30) 0.764
TMB
> = 10
< 10
0.99 (0.13, 7.66) 0.989
Cohort B ALCs
> = 800
< 800
2.63 (1.16, 5.99) 0.021 2.50 (1.05, 5.95) 0.038
CD4 plus CD8 counts
> = 500
< 500
2.70 (1.21, 6.04) 0.016 2.94 (1.18, 7.37) 0.021
PD-L1 IHC
> = 50%
< 50%
2.36 (1.04, 5.37) 0.040 5.21 (1.77, 15.38) 0.003
TMB
> = 10
< 10
3.16 (1.27, 7.86) 0.013 4.11 (1.58, 10.70) 0.004